DE69711221D1 - Metalloproteinase-inhibitoren - Google Patents

Metalloproteinase-inhibitoren

Info

Publication number
DE69711221D1
DE69711221D1 DE69711221T DE69711221T DE69711221D1 DE 69711221 D1 DE69711221 D1 DE 69711221D1 DE 69711221 T DE69711221 T DE 69711221T DE 69711221 T DE69711221 T DE 69711221T DE 69711221 D1 DE69711221 D1 DE 69711221D1
Authority
DE
Germany
Prior art keywords
metalloproteinase inhibitors
inhibitors
conhoh
cooh
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69711221T
Other languages
English (en)
Inventor
Mark Whittaker
Raymond Paul Beckett
Zoe Marie Spavold
Fionna M Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
British Biotech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9625154.1A external-priority patent/GB9625154D0/en
Priority claimed from GBGB9713472.0A external-priority patent/GB9713472D0/en
Application filed by British Biotech Pharmaceuticals Ltd filed Critical British Biotech Pharmaceuticals Ltd
Application granted granted Critical
Publication of DE69711221D1 publication Critical patent/DE69711221D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
DE69711221T 1996-12-04 1997-12-02 Metalloproteinase-inhibitoren Expired - Lifetime DE69711221D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9625154.1A GB9625154D0 (en) 1996-12-04 1996-12-04 Metalloproteinase inhibitors
GBGB9713472.0A GB9713472D0 (en) 1997-06-27 1997-06-27 Metalloproteinase inhibitors
PCT/GB1997/003316 WO1998024759A1 (en) 1996-12-04 1997-12-02 Metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
DE69711221D1 true DE69711221D1 (de) 2002-04-25

Family

ID=26310541

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69711221T Expired - Lifetime DE69711221D1 (de) 1996-12-04 1997-12-02 Metalloproteinase-inhibitoren

Country Status (7)

Country Link
US (1) US5840974A (de)
EP (1) EP0944587B1 (de)
JP (1) JP2001508047A (de)
AT (1) ATE214692T1 (de)
AU (1) AU5230898A (de)
DE (1) DE69711221D1 (de)
WO (1) WO1998024759A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9710490D0 (en) * 1997-05-21 1997-07-16 British Biotech Pharm Metalloproteinase inhibitors
JP3621884B2 (ja) * 1998-01-09 2005-02-16 ファイザー・インク マトリックスメタロプロテアーゼ阻害剤
CA2663132A1 (en) * 2006-09-12 2008-03-20 Commonwealth Scientific And Industrial Research Organisation Acetylenic compounds
UA106967C2 (uk) * 2007-12-20 2014-11-10 Фарма Мар, С.А. Протипухлинні аналоги пептидів, фармацевтична композиція, спосіб одержання сполук та проміжні сполуки

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
US5318964A (en) * 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
DE69412469T2 (de) * 1993-03-16 1999-02-04 British Biotech Pharm Hydroxamsaeurederivate als metalloproteinase inhibitoren
DE69415159T2 (de) * 1993-08-02 1999-07-22 Celltech Therapeutics Ltd Succinamid-derivate, verfahren zu ihrer herstellung und ihre verwendung als gelatinase- und collagenase- inhibitoren
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
KR100418808B1 (ko) * 1994-01-20 2004-07-23 브리티쉬 바이오테크 파마슈티칼스 리미티드 금속단백질분해효소억제제
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
GB9504084D0 (en) * 1995-03-01 1995-04-19 British Biotech Pharm Synthesis of carboxylic and hydroxamic acid derivatives
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
GB9513331D0 (en) * 1995-06-30 1995-09-06 British Biotech Pharm Matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
US5840974A (en) 1998-11-24
JP2001508047A (ja) 2001-06-19
AU5230898A (en) 1998-06-29
EP0944587B1 (de) 2002-03-20
WO1998024759A1 (en) 1998-06-11
ATE214692T1 (de) 2002-04-15
EP0944587A1 (de) 1999-09-29

Similar Documents

Publication Publication Date Title
DK0931788T3 (da) Metalloproteasehæmmere
DE69620443D1 (de) Naphthyl substituierte benzimidazolderivate als antikoagulantien
TR199901653T2 (xx) Fitalazinonlar.
TR200100605T2 (tr) Arilpiperazinler ve bunların metaloproteinaz inhibe edici maddeler (MMP) olarak kullanımı
DE69522569T2 (de) Metalloproteinase hemmende verbindungen
KR950700894A (ko) 탁솔 유도체(Taxol derivatives)
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
TR199802536T2 (xx) Yeni amino asit t�revleri,trombin inhibit�rleri olarak kullan�lmalar�.
NO20024745D0 (no) 2-hydroksymutilinkarbamat-derivater for antibakteriell anvendelse
DE69812634D1 (de) Metalloproteinase-inhibitoren
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
TR200003859T2 (tr) Amidino ve guanidino azetidinon triptaz önleyicileri
DK1377574T3 (da) 6-phenylbenzonaphtyridiner
ATE320422T1 (de) Metalloproteinase inhibitoren
DK0696278T3 (da) Herbicidtvirkende substituerede 1-phenyl- eller 1-pyridinylbenzotriazoler
ATE214692T1 (de) Metalloproteinase-inhibitoren
ATE223226T1 (de) Azazyklohexapeptid-verbindungen
TR200100133T2 (tr) FKBP İnhibitörleri
DK0683777T3 (da) Oxindol-1-N-(alkoxycarbonyl)carboxamider og -1-(N-carboxamido)carboxamider som antiinflammatoriske midler
ATE163402T1 (de) Substituierte ortho- ethenylphenylessigsäurederivate
DK0775113T3 (da) N-substituerede azabicycloheptan-derivater som neuroleptika osv.
TR200001122T2 (tr) Farmasötikler olarak bifenil türevleri.
ATE238781T1 (de) Verwendung von katecholderivaten als proteinaseinhibitoren

Legal Events

Date Code Title Description
8332 No legal effect for de